Clinical Trial

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-12-29; most recent amendment 2024-07-15.
Status change: Not Yet Recruiting → Recruiting 2022-02-13
Trial Details
NCT Number NCT04691661
Lead Sponsor Il-Yang Pharm. Co., Ltd.
Conditions Parkinson Disease
Enrollment 40 participants
Start Date 2021-09-09
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-16